Fresenius Medical Care Reports Q3 2026 Results Amidst Regulatory Headwinds and China Strategy Shifts
Fresenius Medical Care (FMS) reported third-quarter revenue of 4,937 million Euro, a 1% increase driven by organic growth in its Care Delivery and Care Enablement segments. Despite this top-line stability, adjusted operating income fell 6% at constant currency due to inflationary pressures and regulatory challenges. The company is currently navigating significant one-time costs totaling 108 million Euro related to refining its China strategy, which includes exiting the peritoneal dialysis business. Looking ahead, management issued cautious guidance for full-year operating income, narrowing the range toward flat or negative mid-single digit growth. Investors are monitoring substantial projected headwinds for 2027, estimated between 300 million and 350 million Euro due to changes in phosphate binder reimbursement (TDAPA). While share buybacks helped stabilize adjusted EPS at 1.11 Euro, rising costs in logistics and energy continue to pressure margins.
Tickers: $FMS
Topics: cost savings market expansion operating income revenue growth strategic restructuring